Patent intelligence · US
US 10154681
Goitrogen-free beverage, methods of use and method of formulating the same
Goitrogen-free beverage, methods of use and method of formulating the same
Patent details — US 10154681
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 18, 2018
- Expiration
- Dec 13, 2038
- Applicant
- Script Essentials, LLC
- Claims
- 25
- CPC classes
- A61K, A61K36/05, A61K36/23, A61K36/73
Quick answer
US 10154681 (Goitrogen-free beverage, methods of use and method of formulating the same) is held by Script Essentials, LLC. Status: granted. Granted Dec 18, 2018. Expires Dec 13, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Script Essentials, LLC
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K36/05, A61K36/23, A61K36/73, A61K36/88, A61K36/899
More from Script Essentials, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 10154681?
US 10154681 (Goitrogen-free beverage, methods of use and method of formulating the same) is held by Script Essentials, LLC. Status: granted. Granted Dec 18, 2018. Expires Dec 13, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10154681?
Script Essentials, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 10154681 expire?
Our index shows an expiration date of Dec 13, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.